Cawachi Limited
【Kawachi Pharmaceuticals】Q1 2027 Earnings｜Sales 71.9 billion yen (+1.3%)
Kawachi Pharmaceuticals achieved sales of 71.9 billion yen (YoY +1.3%), operating profit of 1.447 billion yen (+15.9%), and net income attributable to owners of the parent of 1.12 billion yen (+5.5%) in the first quarter of the fiscal year ending March 2027. Although the number of stores decreased to 385, profitability was maintained through cost review and sales promotion initiatives.
Key Figures
- Net sales: 71.981 billion yen (YoY +1.3%)
- Operating profit: 1.447 billion yen (YoY +15.9%)
- Net income attributable to owners of the parent: 1.12 billion yen (YoY +5.5%)
AI要約
Overview of Business Performance
Kawachi Pharmaceuticals recorded net sales of 71.981 billion yen (YoY +1.3%), operating profit of 1.447 billion yen (+15.9%), ordinary income of 1.710 billion yen (+6.2%), and net income attributable to owners of the parent of 1.12 billion yen (+5.5%) in the first quarter of the fiscal year ending March 2027. The increase in sales was driven by effects of cost review and sales promotion measures. Despite reducing the number of stores to 385, profitability improved with higher sales and earnings, demonstrating a steady performance trend.
Financial Position and Future Outlook
Total assets decreased slightly from 20.255 billion yen to 20.254 billion yen. However, current assets increased due to higher cash and deposits. Liabilities increased mainly due to an increase in accounts payable, while net assets declined due to dividend payments. The equity ratio slightly decreased to 56.7%. Going forward, the company will continue to focus on cost management and sales promotion to ensure stable earnings.
Kawachi Pharmaceuticals Co., Ltd.
Company overview · Stock price · Financial data · All IR
